• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

HSAs grow despite uncertainties

Article

The Consumer Driven Healthcare Institute?s (CDHCI) quarterly report, ?The Consumer Driven Healthcare (CDHC) Market Data Advisory,? aggregates blind data from millions of actual health savings accounts (HSAs) provided by CDHCI members and partners.

The Consumer Driven Healthcare Institute’s (CDHCI) quarterly report, “The Consumer Driven Healthcare (CDHC) Market Data Advisory,” aggregates blind data from millions of actual health savings accounts (HSAs) provided by CDHCI members and partners. According to the report, total accounts administered in HSA programs on average grew 4% in the first quarter of 2010.

The growth comes amid questions raised by the Patient Protection and Affordable Care Act (PPACA), and how its implementation will affect consumer-driven healthcare.

“Under the PPACA, we anticipate that state health insurance exchanges will allow for inclusion of consumer driven account-based plans that meet the standards prescribed under the law,” says David Randall, executive director of CDHCI in Washington, D.C. “As an example, the Massachusetts Health Connector allows high-deductible health plans to be included as a plan option that employers and individuals can choose from. Further, we expect that consumer driven healthcare will continue to grow as more employers seek these plans as a means of controlling health care costs.”

Additional findings from the report showed employers on average contributed $200 each month into individual HSAs and $238 into family HSAs. Employees, on average, contributed $188 each month into individual HSAs, and $387 into family HSAs.

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Related Content
© 2024 MJH Life Sciences

All rights reserved.